Best Peptides for Fat Loss (2026): Ranked by Clinical Evidence
Tirzepatide, semaglutide, retatrutide, tesamorelin and more, ranked by the strength of human trial evidence for fat loss, with trial results and references.
Peptides for fat loss fall into two distinct categories: appetite and metabolic regulators (the GLP-1 receptor agonist class) and body composition tools that work through growth hormone pathways. This distinction matters whether you're focused on fat loss, overall weight loss, or body-composition changes. In large randomized trials, average weight loss was 14.9% with semaglutide (STEP 1) [1] and 20.9% with tirzepatide (SURMOUNT-1) [3]. Retatrutide reached 24.2% in its peer-reviewed Phase 2 trial [5] and up to 28.3% in Phase 3 topline results that are not yet peer-reviewed [6]. The GH-pathway peptides have strong mechanistic rationale and good pre-clinical data, but human trial quality varies considerably.
This guide ranks each compound by evidence strength for fat loss specifically — not just general health benefits. Where a compound is FDA-approved for a related indication, that's noted. All dosing represents common reference ranges from the research literature; discuss actual use with a qualified healthcare provider.
Evidence Grade Key
⚠ Medical disclaimer: Research peptides discussed here are not FDA-approved for the uses described (exceptions noted). All dosing figures are common reference ranges from research and community literature — not medical prescriptions. Always discuss any compound protocol with a qualified healthcare provider before starting.
Ranked by Evidence
Tirzepatide
Grade A+GLP-1 / GIP Dual Agonist · Metabolic
Backed by multiple human randomized trials, including a head-to-head comparison with semaglutide.
Tirzepatide activates both GLP-1 and GIP receptors simultaneously, suppressing appetite through two distinct pathways, slowing gastric emptying, and improving insulin sensitivity. In SURMOUNT-1, adults with obesity lost an average 20.9% of body weight on 15 mg over 72 weeks [3]. In the head-to-head SURMOUNT-5 trial it produced 20.2% average weight loss vs 13.7% for semaglutide over 72 weeks [4].
Reference Dose Range
2.5–15 mg/week
Titrate slowly — start at 2.5 mg/week, increase every 4+ weeks to manage GI side effects.
Route
Subcutaneous (weekly)
Best for
Significant fat loss goals, metabolic syndrome, insulin resistance, or anyone who plateaued on a GLP-1 monotherapy.
Caveat
GI side effects (nausea, vomiting, constipation) are common during dose escalation. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. FDA-approved as Zepbound (obesity) and Mounjaro (type 2 diabetes).
Semaglutide
Grade A+GLP-1 Receptor Agonist · Metabolic
The most established GLP-1 agonist for fat loss — well-studied, weekly injection, with the most comprehensive safety data in the class.
Semaglutide binds GLP-1 receptors in the hypothalamus (appetite regulation) and GI tract (gastric emptying delay, satiety signaling). Its 7-day half-life allows once-weekly dosing with stable blood levels. In STEP 1, adults with obesity lost an average 14.9% of body weight on 2.4 mg over 68 weeks [1].
Reference Dose Range
0.25–2.4 mg/week
Start at 0.25 mg/week for 4 weeks, then titrate up in 0.25–0.5 mg steps.
Route
Subcutaneous (weekly)
Best for
First-line GLP-1 therapy, those who want the most extensively studied compound in the class, or anyone with cardiovascular risk factors (in the SELECT trial, semaglutide 2.4 mg cut major cardiovascular events by 20% in people with overweight or obesity and existing heart disease, without diabetes [2]).
Caveat
Nausea is the most common side effect during titration. Not appropriate for individuals with personal or family history of medullary thyroid carcinoma. FDA-approved as Wegovy (obesity) and Ozempic (type 2 diabetes).
Retatrutide
Grade AGIP / GLP-1 / Glucagon Triple Agonist · Metabolic
The largest average weight loss of any compound in this guide, but still investigational.
Retatrutide activates three receptors: GLP-1 and GIP, like tirzepatide, plus the glucagon receptor, which is thought to raise energy expenditure. In the peer-reviewed Phase 2 trial, adults with obesity lost an average 24.2% of body weight on 12 mg at 48 weeks [5]. In Lilly's Phase 3 TRIUMPH-1 topline results (May 2026), average weight loss at 80 weeks was 19.0%, 25.9% and 28.3% on 4, 9 and 12 mg vs 2.2% on placebo [6]. TRIUMPH-2 (type 2 diabetes) showed up to 20.8% and TRIUMPH-3 (BMI 35+ with heart disease) up to 22.6% [7].
Reference Dose Range
4–12 mg/week (Phase 3 trial doses)
Trials reached these doses by gradual escalation from a low starting dose.
Route
Subcutaneous (weekly)
Best for
Larger amounts of weight to lose, or people who plateaued on semaglutide or tirzepatide.
Caveat
Grade A reflects a peer-reviewed Phase 2 trial; Phase 3 results so far are company topline releases, not yet peer-reviewed. Not FDA-approved as of October 2026. In TRIUMPH-1, 11.3% of people on 12 mg stopped because of side effects vs 4.9% on placebo [6].
I break down the retatrutide trial data on my YouTube channel:
Tirzepatide vs Retatrutide · Why Retatrutide Makes You Hungrier
Tesamorelin
Grade AGHRH Analog · Metabolic
The only FDA-approved peptide specifically shown to reduce visceral abdominal fat — pulsatile GH stimulation.
Tesamorelin is a stabilized GHRH analog that stimulates natural pulsatile GH release from the pituitary. Clinical trials in HIV-associated lipodystrophy showed significant reductions in trunk fat and visceral adiposity with preserved lean mass. In a 26-week trial of 412 adults with HIV and excess abdominal fat, 2 mg/day reduced visceral fat by 15.2% vs a 5.0% increase on placebo, without significant changes in glucose; IGF-1 rose about 81% [8].
Reference Dose Range
1–2 mg/day
Administered once daily, typically in the abdomen.
Route
Subcutaneous
Best for
Excess visceral/abdominal fat, those seeking GH-pathway fat loss with a proven human track record, or people with metabolically-driven fat distribution.
Caveat
Contraindicated with pituitary tumors, hypopituitarism, or active malignancy. More expensive than most GH secretagogues. Daily injection required. FDA-approved as Egrifta only for excess abdominal fat in HIV-associated lipodystrophy; fat-loss use outside that is off-label.
MOTS-C
Grade CMitochondrial Peptide · Anti-aging
A mitochondria-derived peptide that improves insulin sensitivity and fat oxidation — particularly effective for metabolic-pattern fat.
MOTS-C is encoded within mitochondrial DNA and functions as an exercise-mimetic signaling molecule. It activates AMPK pathways that increase fatty acid oxidation, improve cellular glucose uptake, and enhance mitochondrial efficiency. MOTS-C levels decline significantly with age, correlating with metabolic deterioration. In mice, MOTS-c prevented diet-induced obesity and insulin resistance [9]; there are no completed human fat-loss trials.
Reference Dose Range
0.5–5 mg per dose, 2–3x/week
Often paired with exercise for synergistic metabolic effects.
Route
Subcutaneous
Best for
Metabolic-pattern fat gain (especially visceral), individuals with insulin resistance or declining mitochondrial function, or those seeking fat loss alongside longevity support.
Caveat
Grade C reflects animal data; human safety and effective doses for fat loss are not established.
AOD-9604
Grade CGH Fragment · Body Composition
A fat-specific fragment of growth hormone — stimulates lipolysis without raising blood sugar, IGF-1, or causing other GH side effects.
AOD-9604 is a modified C-terminal fragment of human growth hormone (residues 176–191). In animal studies it increased fat breakdown (lipolysis) and reduced fat formation. Critically, it does not bind the GH receptor responsible for IGF-1 elevation or blood sugar changes — making it a more targeted fat-loss tool compared to full GH or GH secretagogues.
Reference Dose Range
250–500 mcg/day
Best taken fasted, 30 minutes before exercise or in the morning.
Route
Subcutaneous
Best for
People who want GH-mediated fat loss without the full secretagogue protocol, or those targeting stubborn fat deposits while already lean.
Caveat
Six human trials found it well tolerated, with no effect on IGF-1 or blood sugar [10]. But in a 536-person Phase 2b obesity trial, no dose produced weight loss significantly different from placebo, and the developer ended its obesity program in 2007. Not approved for any use.
5-Amino-1MQ
Grade CNNMT Inhibitor · Metabolic / Anti-aging
An experimental small molecule that may reprogram fat cells toward energy expenditure — animal data only, highly experimental. Note: it is a small molecule, not a peptide.
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that depletes SAM methyl donors and suppresses intracellular NAD+ availability. By blocking NNMT, the compound theoretically increases NAD+ levels and shifts adipocyte metabolism from fat storage toward energy expenditure. In diet-induced obese mice, it reduced body weight and white fat without changing food intake [11].
Reference Dose Range
50–150 mg/day
Taken in the morning; divided doses (50 mg 2–3x daily) are common in research literature.
Route
Oral
Best for
Biohackers interested in experimental metabolic compounds — not a first-line fat-loss tool.
Caveat
Grade C — no controlled human trials exist. All mechanistic and efficacy data is from rodent models. Human safety profile is unknown. Consider this highly experimental.
Quick Comparison
All dose figures are educational reference ranges — not prescriptions.
| Compound | Grade | Reference Dose | Route |
|---|---|---|---|
| Tirzepatide | A+ | 2.5–15 mg/week | Subcutaneous (weekly) |
| Semaglutide | A+ | 0.25–2.4 mg/week | Subcutaneous (weekly) |
| Retatrutide | A | 4–12 mg/week (Phase 3 trial doses) | Subcutaneous (weekly) |
| Tesamorelin | A | 1–2 mg/day | Subcutaneous |
| MOTS-C | C | 0.5–5 mg per dose, 2–3x/week | Subcutaneous |
| AOD-9604 | C | 250–500 mcg/day | Subcutaneous |
| 5-Amino-1MQ | C | 50–150 mg/day | Oral |
Conclusion
Tirzepatide and semaglutide have the strongest evidence, with multiple human RCTs and FDA approval for obesity. Retatrutide shows the largest average weight loss in the trials described here, but remains investigational and its Phase 3 results are not yet peer-reviewed. Tesamorelin has human clinical trial data in HIV-associated lipodystrophy. MOTS-C, AOD-9604 and 5-Amino-1MQ have much weaker evidence for fat loss.
Frequently Asked Questions
What are the best peptides for weight loss?
Tirzepatide and semaglutide have the strongest evidence: multiple large randomized controlled trials, and both are FDA-approved for obesity. Retatrutide shows the largest average loss so far but is still investigational. GH-pathway and mitochondrial compounds have much weaker evidence.
Do I need to use a GLP-1 peptide for fat loss, or can I get results with other compounds?
GLP-1 agonists have the strongest human evidence for fat loss — typically 10–22% body weight reduction in clinical trials. The other compounds (AOD-9604, Tesamorelin, MOTS-C) have legitimate mechanisms and supporting data, but their effect sizes in humans are generally smaller. If fat loss is the primary goal, the GLP-1 class is the most evidence-backed starting point. The other compounds are better suited as complements to a broader protocol, or for specific contexts (e.g., Tesamorelin for visceral fat, MOTS-C for metabolic-pattern obesity).
Can peptides for fat loss replace diet and exercise?
No. GLP-1 agonists work in large part by reducing appetite, which creates the caloric deficit that drives fat loss. They don't bypass energy balance — they make it easier to maintain. Resistance training is particularly important during GLP-1 therapy to preserve lean muscle mass, since total weight loss includes some muscle. Nutrition quality matters more than ever when appetite is suppressed. Think of these compounds as powerful tools that support the fundamentals, not replacements for them.
How long before I see results with fat loss peptides?
GLP-1 agonists typically show meaningful fat loss within 4–8 weeks at therapeutic doses, with maximum results at 12–16 weeks and beyond as doses are titrated up. AOD-9604 and Tesamorelin show measurable changes in body composition at 8–12 weeks in clinical trials. MOTS-C effects emerge over several weeks of consistent use. None of these are fast-acting compounds — patience and consistent use are required.
What's the difference between Tirzepatide and Semaglutide for fat loss?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% average weight loss vs 13.7% for semaglutide over 72 weeks [4]. Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates GLP-1 receptors.
Is retatrutide better than tirzepatide?
In separate trials retatrutide produced larger average weight loss (up to 28.3% at 80 weeks in TRIUMPH-1 topline data [6]) than tirzepatide (20.9% at 72 weeks in SURMOUNT-1 [3]), but the two have not been compared head-to-head, retatrutide's Phase 3 data are not yet peer-reviewed, and it is not FDA-approved.
Is it safe to stack multiple fat-loss peptides?
Stacking GLP-1 agonists (e.g., Semaglutide + Tirzepatide) is not recommended due to overlapping mechanisms and cumulative GI side effects. Combining a GLP-1 agonist with a GH-pathway compound (e.g., Semaglutide + Tesamorelin) is used in some clinical contexts but should only be done under medical supervision. AOD-9604 and MOTS-C have different mechanisms and are sometimes used alongside GLP-1 therapy, but there is limited human data on the safety and efficacy of such combinations.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
- Eli Lilly and Company. Retatrutide TRIUMPH-1 Phase 3 topline results (press release), May 21, 2026.
- Eli Lilly and Company. Retatrutide TRIUMPH-2 and TRIUMPH-3 topline results (press release), July 23, 2026.
- Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007;357:2359-2370.
- Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015;21(3):443-454.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152.
Related Resources
Discuss Protocols with Real Practitioners
Join the Hacksmith's Peptalk community for in-depth peptide protocol discussions, dosing Q&As, and member experiences with every compound in this guide.
Join Skool Community →Free to join · No credit card
All dosing figures are educational reference ranges from research literature. Not medical prescriptions. Discuss any protocol with a qualified healthcare provider.